Pharma & CDMO: India as the World's Pharmacy and Contract Partner

Overview

India is a global leader in generic pharmaceuticals, supplying a large share of the world's generic volumes across the US, Europe and emerging markets. Beyond generics, contract development and manufacturing (CDMO) and contract research (CRO) are fast-growing as global innovators diversify supply chains away from China (China+1). The domestic branded-generics market adds a steady, high-margin base.

The CDMO opportunity is strategically important: global pharma and biotech increasingly outsource development and manufacturing, and India offers cost-efficient, quality-compliant capacity. API (active pharmaceutical ingredient) backward integration, aided by PLI, reduces China dependence for key starting materials. Complex generics, biosimilars and specialty products are moving the industry up the value chain.

US generic pricing pressure, regulatory (USFDA) compliance and API cost volatility are perennial challenges. The blend of a defensive domestic market and a growth-oriented export/CDMO opportunity makes the sector a balanced healthcare exposure.

Key Players

Investment Outlook

Indian pharma offers a balanced mix of defensive domestic demand and a structural CDMO growth story, though US generic pricing and compliance remain headwinds. We favour firms with CDMO momentum, complex-generic pipelines and clean regulatory track records.

All figures are indicative and for information only - not investment advice or a recommendation. Market sizes, growth rates and financial metrics are hedged estimates that vary by source and period. Please consult your advisor before investing.